Suppr超能文献

用于治疗炎症性肠病的益生菌

Probiotics for the treatment of inflammatory bowel disease.

作者信息

Veerappan Ganesh R, Betteridge John, Young Patrick E

机构信息

Gastroenterology Service, Department of Medicine, Walter Reed National Military Medical Center, Bethesda, MD 20889-0001, USA.

出版信息

Curr Gastroenterol Rep. 2012 Aug;14(4):324-33. doi: 10.1007/s11894-012-0265-5.

Abstract

Probiotics are organisms which provide a desired and beneficial effect on human health. With recent evidence implicating a disruption in the balance of the gastrointestinal microbiome and intestinal immunity as a potential trigger for inflammatory bowel disease (IBD), there has been growing interest in using probiotics as an adjunct to standard anti-inflammatory and immune suppressing therapy. Animal models describe potential and plausible mechanisms of action for probiotics to counter inflammation of colonic mucosa. Although there are insufficient data to recommend probiotics in ulcerative colitis or Crohn's disease, good evidence supports the use of specific probiotics for maintenance of remission in pouchitis. Although there are limited regulatory standards for the agents, probiotics are relatively safe with minimal reported side effects or contraindications. More rigorous studies need to be published supporting efficacy and safety of these agents before they become a mainstay of IBD medical treatment.

摘要

益生菌是对人体健康产生预期有益影响的生物体。近期有证据表明,胃肠道微生物群和肠道免疫平衡的破坏可能是炎症性肠病(IBD)的潜在触发因素,因此人们越来越有兴趣将益生菌用作标准抗炎和免疫抑制疗法的辅助手段。动物模型描述了益生菌对抗结肠黏膜炎症的潜在且合理的作用机制。尽管尚无足够数据推荐在溃疡性结肠炎或克罗恩病中使用益生菌,但有充分证据支持使用特定益生菌维持储袋炎的缓解。尽管这些制剂的监管标准有限,但益生菌相对安全,报告的副作用或禁忌症极少。在这些制剂成为IBD医学治疗的主要手段之前,需要发表更严格的研究来支持其有效性和安全性。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验